Loading...
Market
Average duration for completing BPaLM regimen in India by end of 2024?
2
Resolution / Starting Odds
Less than 6 months • 25%
6 to 8 months • 25%
8 to 10 months • 25%
More than 10 months • 25%
Union Health Ministry of India's official reports and medical journals
Story
India Approves BPaLM Regimen for Drug-Resistant TB
Sep 6, 2024, 11:51 AM
The Union Health Ministry of India has approved the introduction of a new, shorter, and more efficacious treatment regimen for drug-resistant tuberculosis (TB). The BPaLM regimen, which consists of a four-drug combination—Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin—has been proven to be safe and more effective. This novel treatment will be implemented under the National TB Elimination Program and is expected to benefit India's 75,000 drug-resistant TB patients.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No increase or decrease • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 5 days • 25%
5 to 10 days • 25%
10 to 15 days • 25%
More than 15 days • 25%
More than 20 countries • 33%
10 to 20 countries • 34%
Less than 10 countries • 33%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 10 • 25%
10-20 • 25%
20-30 • 25%
More than 30 • 25%